| Literature DB >> 31601220 |
Qiyi Zhang1, Jingjin Wu2, Yang Tian1, Jixuan Duan3, Yi Shao3, Sheng Yan4, Weilin Wang5.
Abstract
BACKGROUND: The outcomes in patients with pancreatic or ampulla tumors remain unsatisfactory, especially with invasion into the hepatic artery (HA) or the superior mesenteric artery (SMA). In this setting, pancreatectomy combined with arterial resection and reconstruction may offer the possibility of an en-block resection with negative margins and acceptable morbidity and mortality.Entities:
Mesh:
Year: 2019 PMID: 31601220 PMCID: PMC6785878 DOI: 10.1186/s12893-019-0560-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1a Variant right hepatic artery (RHA) from the superior mesenteric artery with tumor invasion. b Gastroduodenal artery remnant used to reconstruct the variant RHA
Fig. 2a A giant solid pseudopaillary tumor (16 cm) located in the pancreatic head and involving the superior mesenteric artery (SMA). b SMA reconstruction using an autologous great saphenous vein. c CT scan of a retroperitoneal ganglioneuroma involving the pancreatic head and SMA. d SMA reconstruction using a size-matched allogeneic frozen iliac artery graft
Fig. 3a A single microvascular clamp was placed on the proximal arterial stump leaving the distal artery free unclamped. b The anastomosis was started with a central stitch on the posterior wall. Subsequent the sutures were advanced counter-clockwise, adjacent to the previous suture. c The first central knot was pulled by the assistant to the left side to improve visualization of the anterior wall anastomosis. d The distal artery was clamped and the anterior wall was completed in a similar manner
Patient Demographics
| Age (year) | 54 (19–78) |
|---|---|
| Sex | |
| Male | 9 |
| Female | 12 |
| Weight (Kg) | 55 (38–70) |
| Height (cm) | 164 (153–178) |
| Tumor diameter (cm) | 4.9 (1.4–16.0) |
| Tumor location | |
| Pancreatic head | 10 |
| Distal pancreas | 2 |
| Total pancreas | 2 |
| Distal CBD | 5 |
| Duodenal ampulla | 2 |
| Pathology | |
| Adenocarcinoma | 18 |
| Moderate differentiation | 15 |
| Poor differentiation | 3 |
| Ganglioneuroma | 2 |
| SPN | 1 |
| Regional metastasis | |
| Yes | 14 |
| No | 7 |
| Distant metastasis | |
| Uncertain | 4 |
| No | 17 |
| Operational time (min) | 589 (187–855) |
| Arterial reconstruction time (min) | 25.1 (21–33) |
| Blood loss (mL) | 723 (200–2000) |
| Post-operative hospital stay (day) | 19 (8–34) |
CBD common bile duct, SPN solid pseudopapillary neoplasm. Data are presented as “mean (range)”
Surgical Outcomes
| Case | Surgery | Invaded artery | Arterial reconstruction | Venous reconstruction | Arterial anatomy |
|---|---|---|---|---|---|
| 1 | PD | ARHA | ARHA-CHA | PV-SMV | ARHA from SMA |
| 2 | PD | RHA | RHA-GDA | No | LHA from LGA; RHA from SMA |
| 3 | PD | RHA | RHA-LHA | No | LHA from LGA; RHA from SMA |
| 4 | TP | CHA & PHA | PHA-CHA | SMV-SMV | Normal |
| 5 | PD | RHA | RHA-GDA | No | RHA from GDA |
| 6 | PD | CHA & PHA | PHA-CHA | SV + SMV- “Y” graft- PV | Normal |
| 7 | PD | CHA | CHA-CHA | No | SMA from Celiac axis, SA from aorta |
| 8 | TP | RHA | RHA-RHA | PV-PV | RHA from CHA |
| 9 | PD | PHA | PHA-LGA | SV + SMV- “Y” graft- PV | Normal |
| 10 | PD | CHA | CHA-CHA | No | Normal |
| 11 | PD | RHA | RHA-RHA | No | Normal |
| 12 | PD | PHA | PHA-CHA | PV-PV; SMV- “Y” graft-SMV | Normal |
| 13 | PD | PHA | PHA-CHA | No | Normal |
| 14 | PD | RHA | RHA-GDA | No | RHA from SMA |
| 15 | PD | CHA & PHA | PHA-CHA | PV-PV | Normal |
| 16 | PD | SMA | SMA-graft-SMA | No | SMA from Celiac axis; LGA from aorta |
| 17 | PD | CHA & PHA | PHA-CHA | PV-PV | Normal |
| 18 | PD | RHA | RHA-GDA | PV-PV | Normal |
| 19 | PD | SMA | SMA-GSV-SMA | No | Normal |
| 20 | PD | SMA | SMA-GSV-SMA | No | Normal |
| 21 | PD | CHA & SMA | CHA-CHA; SMA-GSVSMA | No | Normal |
PD pancreaticoduodenectomy, TP total pancreatectom, DP distal pancreatectomy, ARHA accessory right hepatic artery, CHA common hepatic artery, PHA proper hepatic artery, RHA right hepatic artery, LHA left hepatic artery, GDA gastroduodenal artery, LGA left gastric artery, SMA superior mesenteric artery, SA splenic artery, PV portal vein, SMV superior mesenteric vein, GSV great saphenous vein. Graft: allogeneic frozen iliac vessel
Patient Outcomes and Disease Pathologies
| Case | Sex | Age | Location | Diameter | Pathology | Differentiation | Regional metastasis | Post-operative stay (day) | Complication | Outcome (months, cause of death) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 52 | Distal CBD | 4 | Adenocarcinoma | Moderately | Yes | 19 | None | Deceased (25.9, recurrence) |
| 2 | F | 57 | Distal CBD | 1.5 | Adenocarcinoma | Moderately | Yes | 17 | None | Deceased (27.5, recurrence) |
| 3 | F | 57 | Duodenal ampulla | 2 | Adenocarcinoma | Moderately | Yes | 34 | None | Deceased (9.7, recurrence) |
| 4 | M | 49 | Whole pancreas | 6 | Adenocarcinoma | Moderately | Yes | 25 | None | Deceased (12.9, recurrence) |
| 5 | M | 69 | Uncinate process | 5 | Adenocarcinoma | Poorly | Yes | 20 | None | Deceased (3.1, cerebral infarction) |
| 6 | F | 67 | Pancreatic head | 4 | Adenocarcinoma | Moderately | Yes | 17 | None | Deceased (10, recurrence) |
| 7 | M | 65 | Distal CBD | 4.5 | Adenocarcinoma | Moderately | Yes | – | Bleeding; sepsis | Deceased (0.3, bleeding; infection) |
| 8 | F | 47 | Whole pancreas | 3 | Adenocarcinoma | Moderately | Yes | 34 | None | Deceased (1.8, chemotherapy related) |
| 9 | M | 49 | Pancreatic head | 4 | Adenocarcinoma | Moderately | Yes | 14 | None | Deceased (37.7, recurrence) |
| 10 | M | 67 | Distal CBD | 2 | Adenocarcinoma | Moderately | Yes | 22 | None | Lost (0.7) |
| 11 | F | 54 | Duodenal ampulla | 2 | Adenocarcinoma | Poorly | Yes | 11 | None | Deceased (13.4, recurrence) |
| 12 | F | 53 | Pancreatic head | 4 | Adenocarcinoma | Moderately | Yes | 12 | None | Deceased (11.6, recurrence) |
| 13 | M | 78 | Pancreatic head | 3 | Adenocarcinoma | Moderately | No | 20 | None | Deceased (10, gastroplegia) |
| 14 | F | 56 | Pancreatic head | 3 | Adenocarcinoma | Moderately | Yes | 22 | None | Deceased (17, recurrence) |
| 15 | M | 75 | Pancreatic head | 4 | Adenocarcinoma | Poorly | No | – | Bleeding; sepsis | Deceased (0.6, bleeding; infection) |
| 16 | M | 55 | Distal CBD | 1.4 | Adenocarcinoma | Moderately | No | – | Bleeding; sepsis | Deceased (0.4, bleeding; infection) |
| 17 | F | 60 | Uncinate process | 4 | Adenocarcinoma | Moderately | Yes | 15 | None | Deceased (12.5, recurrence) |
| 18 | F | 30 | Uncinate process | 4 | Adenocarcinoma | Moderately | No | 16 | None | Deceased (11.8, recurrence) |
| 19 | F | 49 | Retroperitoneum with pancreatic head involvement | 11 | Ganglioneuroma | – | No | 21 | Pancreatic fistula (A) | Alive (60.6) |
| 20 | F | 19 | Pancreatic head | 16 | SPT | – | No | 27 | None | Deceased (11.6, recurrence) |
| 21 | F | 23 | Retroperitoneum with pancreatic head involvement | 15 | Ganglioneuroma | – | No | 13 | None | Alive (71) |
M male, F female, CBD common bile duct, SPT solid pseudopapillary tumor
Outcomes of Patient with Pancreatic Adenocarcinoma
| Operative Group | Chemotherapy Group | ||
|---|---|---|---|
| Total Patients | 11 | 11 | |
| Age, mean (yr) | 58 (30–78) | 61 (46–81) | 0.5004 |
| Sex | 1.000 | ||
| Male | 5 (45.6%) | 6 (54.4%) | |
| Female | 6 (54.4%) | 5 (45.6%) | |
| Tumor diameter, mean (cm) | 4 (3–6) | 4.1 (2.5–6) | 0.7399 |
| TNM stage | III | III | |
| Tumor location | 0.0841 | ||
| Pancreatic head | 8 (72.7%) | 6 (54.4%) | |
| Distal pancreas | 1 (9.1%) | 5 (45.6%) | |
| Total pancreas | 2 (18.2%) | 0 (0%) | |
| Chemotherapy protocols | 0.0292 | ||
| GEM | 7 (63.6%) | 2 (18.2%) | |
| GEMOX | 0 (0%) | 2 (18.2%) | |
| GS | 1 (9.1%) | 5 (45.6%) | |
| mFOLFIRINOX | 0 (0%) | 1 (9.1%) | |
| AG | 0 (0%) | 1 (9.1%) | |
| None | 3 (27.3%) | 0 (0%) | |
| Median Survival (mo) | 11.7 (0.6–37.7) | 11.1 (0.7–36.9) | 0.922 |
GEM gemcitabine 1000 mg/m2 days 1, 8, 15 every 4 wks; GEMOX: gemcitabine 1000 mg/m2 days 1, 8, 15 + capecitabine 1660 mg/m2 days 1–21 every 4 wks; GS: gemcitabine 1000 mg/m2 days 1, 8+ tegafur gimeracil oteracil potassium 80-120 mg days 1–14 every 3 wks, mFOLFIRINOX: day 1 oxaliplatin 68 mg/m2 + calcium folinate 400 mg/m2 + irinatecan 135 mg/m2 + 5-fluorouracil 2400 mg/m2 every 2 wks; AG: gemcitabine 1000 mg/m2 + albumin-bound paclitaxel regimens 125 mg/m2 days 1, 8, 15 every 4 wks
Fig. 4The median survival time was 11.6 months in operative group vs. 8.5 months in the chemotherapy group, p > 0.05